Skip to main content
Quest Diagnostics

Lexicon for Clonal Hematopoiesis in Liquid Biopsy

Lexicon for Clonal Hematopoiesis in Liquid Biopsy

Authors: Tell R, Zehir A, Anfora AT, Basu G, Beidelschies M, Compton C, Cristiano S, Godsey JH, Hu J, Johann DJ, Juntilla M, Kansal R, Lo C, Lopez Ramos D, Mahaganapathy V, Merriam D, Rolfo C, Russell H, Singh U, Stetson D, You M, Leiman LC

Citation: Clin Transl Sci. 2025 Dec 26. doi: 10.1111/cts.70463. Online ahead of print.

Specialties: Oncology, Hematology

Related content

Publication
Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-based Tests for Early Cancer Detection
Publication
Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Test FAQ
Haystack MRD Testing
Publication
Analytical Validation of Blood-Derived Tumor Mutation Burden (bTMB) Assays: A Joint Consensus Recommendation of the BLOODPAC bTMB Analytical Validation Working Group
Publication
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.